- Home
- MDWD vs EGAN Comparison
MDWD vs EGAN Comparison
Compare MDWD & EGAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- EGAN
- Stock Information
- Founded
- MDWD 2000
- EGAN 1997
- Country
- MDWD Israel
- EGAN United States
- Employees
- MDWD N/A
- EGAN N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- EGAN Computer Software: Prepackaged Software
- Sector
- MDWD Health Care
- EGAN Technology
- Exchange
- MDWD Nasdaq
- EGAN Nasdaq
- Market Cap
- MDWD 184.8M
- EGAN 179.4M
- IPO Year
- MDWD 2014
- EGAN 1999
- Fundamental
- Price
- MDWD $18.16
- EGAN $6.50
- Analyst Decision
- MDWD Strong Buy
- EGAN Buy
- Analyst Count
- MDWD 1
- EGAN 2
- Target Price
- MDWD $25.00
- EGAN $9.50
- AVG Volume (30 Days)
- MDWD 66.5K
- EGAN 144.5K
- Earning Date
- MDWD 11-26-2024
- EGAN 02-06-2025
- Dividend Yield
- MDWD N/A
- EGAN N/A
- EPS Growth
- MDWD N/A
- EGAN 37.92
- EPS
- MDWD N/A
- EGAN 0.19
- Revenue
- MDWD $19,720,000.00
- EGAN $90,426,000.00
- Revenue This Year
- MDWD $10.37
- EGAN $1.52
- Revenue Next Year
- MDWD $26.36
- EGAN $10.05
- P/E Ratio
- MDWD N/A
- EGAN $33.99
- Revenue Growth
- MDWD N/A
- EGAN N/A
- 52 Week Low
- MDWD $11.04
- EGAN $4.71
- 52 Week High
- MDWD $24.00
- EGAN $7.96
- Technical
- Relative Strength Index (RSI)
- MDWD 53.58
- EGAN 56.90
- Support Level
- MDWD $15.80
- EGAN $6.33
- Resistance Level
- MDWD $19.60
- EGAN $7.33
- Average True Range (ATR)
- MDWD 0.94
- EGAN 0.40
- MACD
- MDWD 0.12
- EGAN -0.01
- Stochastic Oscillator
- MDWD 62.11
- EGAN 54.89
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About EGAN eGain Corporation
eGain Corp automates customer engagement with an innovative Software as a service (SaaS) platform, powered by deep digital, Artificial intelligence (AI), and knowledge capabilities. It operates in the United States, the United Kingdom, and India. The company derives maximum of its revenues from North America. It provides its products to industries such as financial services, telecommunications, retail, government, healthcare, and utilities.